Skip to content

The EU Registry for the IlluminOss® Bone Stabilization System

The EU Registry for the IlluminOss® Bone Stabilization System - EU Registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON36825
Enrollment
72
Registered
2012-12-20
Start date
2012-10-01
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bone fracture fracture

Interventions

None listed

Sponsors

IlluminOss Medical, Inc.
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: All patients who received the device under compassionate use or palliative care conditions will be asked to participate in the registry (retrospective). In addition, patients who have broken a phalange, metacarpal, distal radius, radius, ulna, clavicle, olecranon and/or fibula and will be treated with an IlluminOss device will be asked to participate in the registry (prospective).

Exclusion criteria

Exclusion criteria: Contra-indications: 1.Skeletally immature men and women 2.Patients with distant foci of infections with may spread to the implant site. 3.Patients allergic to implant materials or dental glue 4. An intramedullary canal smaller than 3,5 mm (diameter) at site of the fracture. 5. Uncooperative patient or patient with neurological disorder, incapagle of following directions. 6. Patients with concomitant metabolic disorders which may impair bone formation. 7. Patients with osteomalacia 8. Patients with distant foci of infections with may spread to the implant site. 9. Patients with marked bone loss or bone resorption. 10. Vaccular insufficiency, muscleatrophy or neuromuscularcular diseases. 11. Patients with open fractures with severe contamination 12.Extremely comminuted fractures where insufficient holding power of the balloon on the intramedullary canal is probable. 13.Patients where the delivery sheath is unable to pass fracture after adequate reduction and alignment.

Design outcomes

Primary

MeasureTime frame
n.v.t.

Secondary

MeasureTime frame
n.v.t.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)